Interchangeability and predictive performance of empirical tolerance models

Clinical Pharmacokinetics

Volumn 36, Issue 2, 1999, Pages 145-167

  Gårdmark, Marie ^a   Brynne, Lena ^a   Hammarlund Udenaes, Margareta ^a   Karlsson, Mats O ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ALPRAZOLAM; CAFFEINE; COCAINE; FUROSEMIDE; GLUCOCORTICOID; GLYCERYL TRINITRATE; ITURELIX; MORPHINE; NICOTINE; NIFEDIPINE; PROPRANOLOL; REMOXIPRIDE;

ARTICLE; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG TOLERANCE; HUMAN; MODEL; PREDICTION; PRIORITY JOURNAL;

EID: 0033023485     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199936020-00005     Document Type: Article

References (47)

1. 1. Castañeda-Hernández G, Caille G, du Souich P. Influence of drug formulation on drug concentration-effect relationships. Clin Pharmacokinet 1994; 26: 135-43
2. 2. Bauer JA, Fung HL. Pharmacodynamic models of nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Pharm Res 1994; 11: 816-23
3. 3. Movin-Osswald G, Hammarlund-Udenaes M. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra-and interindividual aspects. J Pharmacol Exp Ther 1995; 274: 921-7
4. 4. Pratt JA. Psychotropic drug tolerance and dependence: common underlying mechanisms? In: Pratt JA, editor. The biological bases of drug tolerance and dependence. London: Academic Press, 1991: 1-28
5. 5. Way EL. Opioid tolerance and physical dependence and their relationship. In: Hera A, editor. Opioids II. Berlin: Springer-Verlag, 1993: 573-96
6. 6. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Rall TW, Nies AS, et al. editors. The pharmacological basis of therapeutics. New York: Pergamon, 1990: 533
7. 7. Collin E, Cesselin F. Neurobiological mechanisms of opioid tolerance and dependence. Clin Neuropharmacol 1991; 14: 465-88
8. 8. Johnson SM, Fleming WF. Mechanism of cellular adaptive sensitivity changes: application to opioid tolerance and dependence. Pharmacol Rev 1989; 41: 435-88
9. 9. Porchet HC, Benowitz NL, Sheiner LB. Pharmacodynamic model of tolerance: application to nicotine. J Pharmacol Exp Ther 1988; 244: 231-6
10. 10. Hammarlund MM, Odlind B, Paalzow LK. Acute tolerance to furosemide diuresis in humans: pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1985; 233: 447-53
11. 11. Sheiner LB. Clinical pharmacology and the choice between theory and empiricism. Clin Pharmacol Ther 1989; 46: 605-15
12. 12. Shi J, Benowitz NL, Denaro CP, et al. Pharmacokinetic-pharmacodynamic modeling of caffeine: tolerance to pressor effects. Clin Pharmacol Ther 1993; 53: 6-14
13. 13. Ekblom M, Hammarlund-Udenaes M, Paalzow L. Tolerance development and rebound effects of morphine in relation to different administrations in rats. J Pharmacol Exp Ther 1993; 266: 244-52
14. 14. Gårdmark M, Ekblom M, Bouw R, et al. Quantification of effect delay and acute tolerance development to morphine in the rat. J Pharmacol Exp Ther 1993; 267: 1061-7
15. 15. Ouellet DM-C, Pollack GM. A pharmacokinetic-pharmacodynamic model of tolerance to morphine analgesia during infusion in rats. J Pharmacokinet Biopharm 1995; 23: 531-49
16. 16. Fattinger K, Verotta D, Benowitz NL. Pharmacodynamics of acute tolerance to multiple nicotinic effects in humans. J Pharmacol ExpTher 1997; 281: 1238-46
17. 17. Lau CE, Heatherington AC. Pharmacokinetic-pharmacodynamic modeling of stimulatory and sedative effects of alprazolam: timing performance deficits. J Pharmacol Exp Ther 1997; 283: 1119-29
18. 18. Lau CE, Fang MA, Foster DM, et al. Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: timing performance deficits. J Pharmacol Exp Ther 1999; 288: 535-43
19. 19. Ekblad EBM, Licko V. A model eliciting transient responses. Am J Physiol 1984; 246: R114-21
20. 20. Holford NHG, Gabrielsson JL, Sheiner LB, et al. A physiological pharmacodynamic model for tolerance to cocaine effects on systolic blood pressure, heart-rate and euphoria in human volunteers: measurement and kinetics of in vivo drug effects. Noordwijk (The Netherlands): LACDR, 1990: 48
21. 21. Xu Z-X, Sun Y-N, DuBois DC, et al. Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. J Pharmacokinet Biopharm 1995; 23: 163-81
22. 22. Wakelkamp M, Alvan G, Gabrielsson J, et al. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin Pharmacol Ther 1996; 60: 75-88
23. 23. Gårdmark M, Höglund AU, Hammarlund Udenaes M. Aspects on tail-flick, hot-plate and electrical stimulation tests for morphine antinociception. Pharmacol Toxicol 1998; 83: 252-8
24. 24. Sharma A, Ebling WF, Jusko WJ. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci 1998; 87: 1577-84
25. 25. Sun Y, McKay LI, DuBois DC, et al. Pharmacokinetic/pharmacodynamic models for corticosteroids receptor down-regulation and glutamine synthetase induction in rat skeletal muscle by a receptor/gene-mediated mechanism. J Pharmacol Exp Ther 1999; 288: 720-8
26. 26. Francheteau P, Steimer J-L, Merdjan H, et al. A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers. J Pharmacokinet Biopharm 1993; 21: 489-514
27. 27. Veng-Pedersen P, Modi NB. A system approach to pharmacodynamics: input-effect control system analysis of central nervous system effect of alfentanil. J Pharm Sci 1993; 82: 266-75
28. 28. Mandema JW, Wada DR. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. J Pharmacol Exp Ther 1995; 275: 1185-94
29. 29. Fattinger KE, Verotta D, Porchet HC, et al. Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. Am J Physiol 1996; 271: E775-8
30. 30. Chow MJ, Ambre JJ, Ruo TI, et al. Kinetics of cocaine distribution, elimination, and chronotropic effects. Clin Pharmacol Ther 1985; 38: 318-24
31. 31. Kroboth PD, Smith RB, Erb RJ. Tolerance to alprazolam after intravenous bolus and continuous infusion: psychomotor and EEG effects. Clin Pharm Ther 1988; 43: 270-7
32. 32. Ambre JJ, Belknap SM, Nelson J, et al. Acute tolerance to cocaine in humans. Clin Pharmacol Ther 1988; 44: 1-8
33. 33. Lima JJ, Krukemyer JJ, Boudoulas H. Drug-or hormone-induced adaptation: model of adrenergic hypersensitivily. J Pharmacokinet Biopharm 1989; 17: 347-64
34. 34. Holford NHG. Parametric models of the time-course of drug action. In: van Boxtel CJ, Holford NHG, Danhof M, editors. The in vivo study of drug action. Amsterdam: Elsevier, 1992: 61-9
35. 35. Segre G, Turco GL, Vercellone G. Modelling blood glucose and insulin kinetics in normal, diabetic and obese subjects. Diabetes 1972; 22: 94-103
36. 36. Ceresa F, Ghemi F, Martini PF, et al. Control of blood glucose in normal and diabetic subjects. Diabetes 1968; 17: 570-8
37. 37. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis. Stockholm: Swedish Pharmaceutical Press, 1994
38. 38. Movin-Osswald G, Hammarlund-Udenaes M. Remoxipride: pharmacokinetics and effect on plasma prolactin. Br J Clin Pharmacol 1991; 32: 355-60
39. 39. Beal SL, Sheiner LB. NONMEM Users's Guides: NONMEM Project Group. San Francisco: University of California at San Francisco, 1992
40. 40. Jonsson EN, Karlsson MO. X-pose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64
41. 41. Mathsoft. S-PLUS Reference manual, version 3.4. Seattle: Mathsoft, 1997
42. 42. Paalzow LK, Edlund PO. Multiple receptor responses: a new concept to describe the relationship between pharmacological effects and pharmacokinetics of a drug: studies on clonidine in the rat and cat. J Pharmacokinet Biopharm 1979; 7: 495-510
43. 43. Shafer SL, Varvel JR, Aziz N, et al. Pharmacokinetics of fentanyl administrated by computer-controlled infusion pump. Anesthesiology 1990; 73: 1091-102
44. 44. Francheteau P, Steimer J-L, Dubray C, et al. Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203-922. J Pharmacokinet Biopharm 1991; 19: 287-309
45. 45. Gårdmark M, Hammarlund-Udenaes M. Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat: pharmacokinetic-pharmacodynamic modelling. Pain 1998 Feb; 74 (2-3): 287-96
46. 46. Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987; 317: 799-804
47. 47. Kleinbloesem CH, van Brummelen D. Danhof M, et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 1987; 41: 20-30